Treatment
mFOLFIRINOX clinical trials
We’re tracking 39 recruiting studies that include mFOLFIRINOX, each written for real people, not researchers, below.
Recruiting studies
- NCT07114861RecruitingPhase 1/Phase 2
KN510713 with mFOLFIRINOX for advanced pancreatic cancer
This study tests a new drug (KN510713) combined with the standard chemotherapy mFOLFIRINOX for people with advanced pancreatic cancer that hasn't had prior chemotherapy. The goal is to see if adding the new drug can improve outcomes.
Goyang-siAges 19–75 - NCT05968326RecruitingPhase 2
Chemo plus new vaccines versus chemo alone after pancreatic surgery
This Phase 2 trial tests whether adding two study medicines (an immune-based vaccine treatment plus atezolizumab) to standard chemo helps prevent pancreatic cancer from coming back after surgery. It compares the combination against standard chemo alone, looking at safety and how well it prevents relapse.
Los Angeles, CaliforniaAges 18 years+ - NCT06149689RecruitingPhase 2
Chemo plus radiation for advanced pancreatic cancer with normal CA19-9
This trial tests whether giving a strong chemotherapy combination (mFOLFIRINOX) together with radiation therapy can help people with advanced pancreatic cancer who have normal CA19-9 levels. It aims to see if this approach is more effective for this specific group of patients.
ShanghaiAges 18–80 - NCT06079346RecruitingPhase 2/Phase 3
New drug with chemotherapy for advanced pancreatic cancer
This trial tests a new drug called OT-101 combined with a standard chemotherapy regimen (mFOLFIRINOX) for people with advanced pancreatic cancer that has spread or cannot be removed. The goal is to see if the combination can help shrink or control the cancer better than chemotherapy alone.
Detroit, MichiganAges 18 years+ - NCT07044453RecruitingPhase 2/Phase 3
Extra chemo tailored to tumor stage for operated pancreatic cancer
This trial tests whether giving different types of extra chemo (after surgery) based on the stage of your cancer can help prevent it from coming back. It's for people with pancreatic cancer who already had chemo and surgery.
RouenAges 18 years+ - NCT05083247RecruitingPhase 2
Pre-surgery chemotherapy plus targeted radiation for borderline pancreatic cancer
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
AntwerpAges 18 years+ - NCT05179889RecruitingPhase 2/Phase 3
Chemo after surgery for high-risk stage III colon cancer
This trial tests giving mFOLFIRINOX chemotherapy after curative surgery for people with high-risk stage III colon cancer. It aims to lower the chance that cancer comes back.
DaejeonAges 20–75 - NCT06151262RecruitingPhase 2
Trilaciclib plus mFOLFIRINOX for advanced pancreatic cancer
This trial tests a new drug, trilaciclib, combined with a standard chemotherapy regimen (mFOLFIRINOX) for people with advanced pancreatic cancer who have not yet had treatment. The goal is to see if adding trilaciclib can help reduce side effects and improve how well the treatment works.
Nanjing, JiangsuAges 18–75 - NCT06249321RecruitingPhase 2
Chemo plus radiation for advanced pancreatic cancer with normal CA19-9
This trial tests a combination of chemotherapy (mFOLFIRINOX) and radiation therapy for people with advanced pancreatic cancer that has stopped responding to chemotherapy and whose CA19-9 tumor marker levels are normal. The goal is to see if this approach can help when standard treatments are no longer working.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06572813RecruitingPhase 1/Phase 2
Combination therapy for advanced pancreatic cancer
This trial tests whether adding bortezomib and an immunotherapy drug to standard chemotherapy can help people with pancreatic cancer that has spread to other organs. It is for patients who have not had treatment or whose cancer has worsened after gemcitabine-based chemotherapy.
Hangzhou, ZhejiangAges 18–75 - NCT06648434RecruitingPhase 1
MK2 inhibitor plus mFOLFIRINOX for metastatic pancreatic cancer
This trial tests an experimental drug called zunsemetinib (an MK2 inhibitor) combined with a standard chemotherapy regimen (mFOLFIRINOX) for people with pancreatic cancer that has spread to other organs. The goal is to see if the combination works better than chemotherapy alone.
St Louis, MissouriAges 18 years+ - NCT06757244RecruitingPhase 2
Dovipa: Immunotherapy and vitamin D with chemo for advanced pancreatic cancer
This trial tests whether combining the immunotherapy dostarlimab with vitamin D3 and standard chemotherapy (mFOLFIRINOX) can help people with stage IV pancreatic cancer. It aims to see if this new approach is safe and effective.
MarseilleAges 18–75 - NCT07043270RecruitingPhase 2
Alternating chemo regimens for borderline resectable pancreatic cancer
This trial compares two chemotherapy regimens — GnP (gemcitabine and nab-paclitaxel) and mFOLFIRINOX — given in alternating cycles for people with borderline resectable pancreatic cancer. The goal is to see if this alternating approach can shrink the tumor enough to allow surgery.
Lebanon, New HampshireAges 18 years+ - NCT07409272RecruitingPhase 3
Study of setidegrasib with chemo for pancreatic cancer
This trial tests a new drug called setidegrasib, given with two types of chemotherapy (mFOLFIRINOX or NALIRIFOX), for people whose pancreatic cancer has spread and has a specific genetic change called KRAS G12D. The goal is to see if adding setidegrasib helps control the cancer better than chemo alone.
Tucson, ArizonaAges 18 years+ - NCT07283705RecruitingPhase 2
Study of BMS-986504 for MTAP-deleted pancreatic cancer
This trial tests a new drug, BMS-986504, in people with pancreatic cancer that has a specific genetic change called MTAP deletion. The study aims to see if this drug can help shrink or control the tumor.
Houston, TexasAges 18 years+ - NCT05825066RecruitingPhase 2
Chemotherapy before surgery for advanced pancreatic cancer
This trial tests giving chemotherapy before any surgery to people with borderline resectable or locally advanced pancreatic cancer. The goal is to shrink the tumor, which may make surgery more successful and improve outcomes.
Winston-Salem, North CarolinaAges 18 years+ - NCT05534087RecruitingPhase 3
Blood test guided chemo after colon cancer surgery
This study tests whether giving additional (adjuvant) chemotherapy based on a special blood test—circulating tumor DNA (ctDNA)—can lower the risk of colon cancer coming back. It targets people with stage II–III colon cancer whose blood test is positive for minimal residual disease (MRD) after completing standard chemo.
BusanAges 19–75 - NCT04911816RecruitingPhase 1/Phase 2
Pre-surgery chemo plus oral hydroxychloroquine for pancreatic cancer
This trial studies giving chemo and hydroxychloroquine before surgery for resectable pancreatic cancer. The goal is to shrink the tumor and improve the chances of successful removal.
Morgantown, West VirginiaAges 18 years+ - NCT04452461RecruitingPhase 2
Chemotherapy before surgery for borderline pancreatic cancer
This trial tests giving chemotherapy before surgery for people with borderline resectable pancreatic cancer, to try to make surgery more successful. It also checks whether the study treatment is safe and helps tumors before the operation.
Hamilton, OntarioAges 18–79 - NCT07096362RecruitingPhase 2
Using a blood test to guide treatment for advanced pancreatic cancer
This trial tests whether a blood test that detects tumor DNA can help doctors decide early if the standard chemotherapy is working, and if switching treatment might be better. It is for people newly diagnosed with metastatic pancreatic cancer who are starting their first chemotherapy.
Miami, FloridaAges 18 years+ - NCT05677490RecruitingPhase 3
Chemo options, with or without nivolumab, for HER2-negative stomach cancer
This Phase 3 trial compares two standard chemotherapy regimens for advanced stomach, esophagus, or gastroesophageal junction cancer that is HER2-negative. It also tests whether adding nivolumab (an immune therapy) improves outcomes.
Birmingham, AlabamaAges 18 years+ - NCT05912075RecruitingPhase 1
New pre-surgery radiation plus ASTX660 for rectal cancer
This early-phase trial tests adding ASTX660 (a new drug) to pre-surgery radiation for locally advanced rectal cancer. It aims to improve control of the tumor before surgery, making it more likely that the surgeon can remove it with clear margins.
Lyon, RhöneAges 18 years+ - NCT05174169RecruitingPhase 2/Phase 3
Adjuvant colon chemotherapy guided by tumor DNA results
This trial tests whether treatment for colon cancer after surgery can be guided by a blood test that looks for leftover cancer signals (ctDNA). It may help some people choose stronger or different chemo based on whether ctDNA is found after surgery.
Birmingham, AlabamaAges 18 years+ - NCT07255404RecruitingPhase 2
Testing pumitamig with chemotherapy for untreated pancreatic cancer
This trial tests an experimental drug called pumitamig combined with standard chemotherapy for people with advanced pancreatic cancer that has spread and has not been treated yet. The goal is to see if this combination is safe and effective.
Bedford ParkAges 18 years+
What mFOLFIRINOX is being studied for
Conditions with recruiting mFOLFIRINOX studies.
- Pancreatic cancer
- Pancreatic Adenocarcinoma
- Borderline Resectable Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Colon Cancer Stage III
- Colon Cancer
- Advanced Esophageal Adenocarcinoma
- Advanced Gastric Adenocarcinoma
- Advanced Gastroesophageal Junction Adenocarcinoma
Common questions
- Are there clinical trials studying mFOLFIRINOX?
- Yes. Clin2 currently lists 39 recruiting studies that include mFOLFIRINOX, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a mFOLFIRINOX trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is mFOLFIRINOX an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether mFOLFIRINOX or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.